Healthy Brains & Behavior: Understanding and Treating Youth Aggression

NCT ID: NCT00842439

Last Updated: 2016-08-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 335 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-02-28
• Study Completion Date: 2012-08-31

Brief Summary

Understanding the joint neurobiological and social bases to aggression is critical to future attempts to tackle this major public health problem. The overarching goals are: (a) to conduct perhaps the most systematic integration of biosocial risk factors for childhood aggression in order to predict later aggression, (b) to conduct one of the very few biosocial interventions on childhood aggression, (c) to predict and treat two fundamentally different manifestations of aggression proactive and reactive aggression which likely have different etiologies and responsiveness to treatment. The specific aims are: (1) to assess biological (genetic, neurocognitive, brain imaging, neuroendocrinological, neurotoxin, psychophysiological, nutritional), psychosocial (neighborhood, family, school, peer, psychological) and psychiatric (ADHD, CD, ODD, depression, anxiety, PTSD, schizophrenia-spectrum) risk factors for male and female aggression in order to better predict later aggression, (2) to improve prediction by identifying the genetic, neuroimaging, psychophysiological, and neuroendocrinological factors that protect children who are socially at risk for a violence outcome, (3) to develop a genetic mouse model of aggression to test the effectiveness of nutritional interventions in reducing aggression, (4) to begin to develop a new biosocial approach to the treatment and prevention of aggression, based on both cognitive-behavioral and nutrition interventions, (5) to assess the differential prediction and treatment of two fundamental variants of child aggression: proactive and reactive aggression. The human sample will consist of 500 male and female 11-year-old children drawn from high-risk communities in Philadelphia. Three hundred participants will engage in a baseline assessment for risk factors for aggression, and then be randomly assigned to one of four three-month intervention programs: treatment-as-usual, cognitive-behavioral intervention, nutrition supplementation, or CBI + nutrition. Aggression outcome will be assessed throughout intervention and post-intervention.

The investigators believe that biological risk factors will interact with social risk factors in predicting aggression, over and above main effects of these classes of risk factors. Treatment effectiveness will interact with risk factors: those with low omega-3 and high lead exposure at intake will benefit most from the nutritional intervention; those with cognitive and affective risk factors will benefit most from the neuro-cognitive-behavioral intervention.

Conditions

Aggression

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: SINGLE

Study Groups

Cognitive Behavioral Intervention (CBI)

Participants will meet with an interventionist once a week for 12 weeks. They will discuss the child's behavior, will learn coping skills and how to deal with other people.

Group Type: EXPERIMENTAL

CBI

Intervention Type: BEHAVIORAL

Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.

Nutritional Supplements (NUT)

Participants will be asked to take omega-3 supplements, multivitamin tablets, and calcium tablets every day for 12 weeks.

Group Type: EXPERIMENTAL

NUT

Intervention Type: DIETARY_SUPPLEMENT

Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.

CBI + NUT

Participants will receive both the cognitive behavioral intervention and the nutritional supplements.

Group Type: EXPERIMENTAL

CBI

Intervention Type: BEHAVIORAL

Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.

NUT

Intervention Type: DIETARY_SUPPLEMENT

Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.

No intervention

Participants will not be asked to come for sessions or any other intervention. They will receive a list of the types of help that are available if they are interested in following up on their own.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

CBI

Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.

Intervention Type: BEHAVIORAL

NUT

Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

Entry into risk assessment component:

• Must be identified by their health care provider as meeting study criteria.
• Must be 11 or 12 years old
• Can be from the general population or who exhibit problem or aggressive behavior.
• Determination if the child meets criteria for enrollment into the at-risk risk group who will be entered into the RCT will be determined by the PI at the completion of the risk assessment day.
• Participant can be of any racial or ethnic background.
• Both youth and parent must be able to speak and understand English and able to provide informed assent/consent.

Entry into intervention component:

• Entry will be determined by the findings of the risk assessment that is conducted on study entry.
• Participants diagnosed with oppositional defiant disorder or have a borderline diagnosis
• Participants diagnosed with conduct disorder or have a borderline diagnosis
• Participants who score one standard deviation above the (normed population) mean on the either the reactive or proactive components of the Reactive-Proactive Aggression questionnaire
• Participants who score one standard deviation above the mean on the aggression subscale of the CBC, will be entered into the clinical trial
• These criteria may be relaxed slightly to ensure that we have sufficient participants in the intervention phase of the study.

Exclusion Criteria

• A diagnosed psychotic disorder
• Mental retardation
• Claustrophobia
• Currently under psychiatric care
• Pervasive developmental disorders
• Conditions that preclude participation (or increase risk) in the clinical trial (Type 1 diabetes mellitus; metabolic diseases, gastro-intestinal disorders affecting nutrient absorption, cancer)
• Currently on medication that may modify lipid metabolism
• Extensive use of nutritional supplements within the previous 3 months
• Seafood allergy
• Presence or history of orthopedic circumstances and metallic inserts interfering with MR scanning; 11) pregnant in the case of females.
• There are no exclusions by sex or race/ethnicity.

• Minimum Eligible Age: 11 Years
• Maximum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Pennsylvania Department of Health

OTHER_GOV

Sponsor Role: collaborator

University of Pennsylvania

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Adrian Raine, D.Phil.

Role: PRINCIPAL_INVESTIGATOR

University of Pennsylvania

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Countries

United States

References

Raine A, Gur RC, Gur RE, Richmond TS, Hibbeln J, Liu J. Omega-3 Supplementation Reduces Schizotypal Personality in Children: A Randomized Controlled Trial. Schizophr Bull. 2024 Aug 27;50(5):1117-1126. doi: 10.1093/schbul/sbae009.

Reference Type: DERIVED

PMID: 38300759 (View on PubMed)

Raine A, Cheney RA, Ho R, Portnoy J, Liu J, Soyfer L, Hibbeln J, Richmond TS. Nutritional supplementation to reduce child aggression: a randomized, stratified, single-blind, factorial trial. J Child Psychol Psychiatry. 2016 Sep;57(9):1038-46. doi: 10.1111/jcpp.12565. Epub 2016 May 11.

Reference Type: DERIVED

PMID: 27166583 (View on PubMed)

Other Identifiers

SAP # 4100043366

Identifier Type: -

Identifier Source: secondary_id

808689

Identifier Type: -

Identifier Source: org_study_id